Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Picard Medical, Inc. ( (PMI) ) has provided an update.
On March 17, 2026, Picard Medical announced that a 29-year-old patient successfully received a donor heart transplant on February 24, 2026, after being sustained entirely by the SynCardia Total Artificial Heart for more than four years. Implanted on September 2, 2021, the device replaced both ventricles and all four native valves and maintained circulation for 1,636 days, underscoring the system’s ability to support critically ill patients at home for extended periods.
The case highlights the role of total artificial heart therapy as a bridge to transplant for patients with irreversible biventricular heart failure who cannot be managed with left ventricular assist devices. By demonstrating very long-duration support in a single patient within a broader record of more than 2,100 implants worldwide, the outcome reinforces SynCardia’s clinical relevance, informs evolving practice in mechanical circulatory support and may strengthen the company’s positioning in the advanced heart failure treatment market.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on the NYSE American, is the parent of Tucson-based SynCardia Systems, which develops, manufactures and commercializes the SynCardia Total Artificial Heart for patients with end-stage biventricular heart failure. The SynCardia device is the first total artificial heart approved by both the U.S. FDA and Health Canada and is currently the only commercially available artificial heart in the United States and Canada, with more than 2,100 implants performed across 27 countries, making it the most widely used and extensively studied artificial heart globally.
Average Trading Volume: 826,289
Technical Sentiment Signal: Strong Sell
See more data about PMI stock on TipRanks’ Stock Analysis page.